Without direct Iressa comparison, NICE wants more on Roche's Tarceva for NSCLC
This article was originally published in Scrip
Executive Summary
In new draft guidance, NICE, the health technology appraisal institute for England and Wales, has not recommended Roche's erlotinib (Tarceva) for the first-line treatment of locally advanced or metastatic EFGR mutation-positive non-small-cell lung cancer (NSCLC), instead requesting further information from the company.